Simulations Plus, Inc.
Price data unavailable
Track SLP in your trading journalAbout Simulations Plus, Inc.
Simulations Plus, Inc. (SLP) is a US-listed equity tracked across major market indices. Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
The company reports trailing twelve-month revenue of $18.30M and net income of $4.54M. Key metrics include a return on equity of 3.4%, a debt-to-equity ratio of 0.10.
FINOTAUR provides free research summaries, news aggregation, and fundamentals for SLP to support both active traders and long-term investors.
Fundamentals
| Revenue (TTM) | $18.31M |
| Net Income (TTM) | $4.54M |
| EPS (TTM) | — |
| P/E Ratio | — |
| Return on Equity | 3.39% |
| Debt-to-Equity | 0.10 |
| Dividend per Share | — |
Recent News
- GlobeNewswire Inc.·Apr 27
Global Biosimulation Market Poised for Phenomenal Expansion at a CAGR of ~17% by 2034 | DelveInsight
- Benzinga·Apr 22
Certara Strategic Business Divestiture Comes At Right Time, Says Analyst
- Benzinga·Apr 10
Stock Market Today: S&P 500 Futures Pare Losses As March CPI Rises In-Line With Expectations—Taiwan Semiconductor, Rocket Lab In Focus (UPDATED)
Want real-time analysis on SLP?
Track it free in your trading journal. Log trades, tag setups, and review your edge.